Clinical trial
Study of Opebacan in Patients Undergoing Myeloablative Allogeneic Hematopoietic…
NCT00454155 · XOMA (US) LLC, Industry · Terminated
Key facts
| NCT number | NCT00454155 |
|---|---|
| Title | Study of Opebacan in Patients Undergoing Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) |
| Official title | A Phase I/II Study of the Safety and Pharmacokinetics of Opebacan (rBPI21) in Patients Undergoing Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) |
| Acronym | HSCT |
| Lead sponsor | XOMA (US) LLC, Industry |
| Status | Terminated |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Graft Versus Host Disease |
| Intervention type | Drug |
| Interventions | Opebacan |
| Enrollment | 6 |
| Start date | Feb 1, 2007 |
| Primary completion | Jun 1, 2010 |
| Completion | Jun 1, 2010 |
| First posted | Mar 30, 2007 |
| Last update posted | Jul 30, 2012 |
| Countries | United States |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: